Buy Or Sell Opportunity • May 20
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 2.1% to US$84.10. The fair value is estimated to be US$107, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 9.6% per annum. Earnings are also forecast to grow by 28% per annum over the same time period. Declared Dividend • May 18
First quarter dividend of US$0.52 announced Shareholders will receive a dividend of US$0.52. Ex-date: 30th June 2026 Payment date: 16th July 2026 Dividend yield will be 2.3%, which is lower than the industry average of 7.4%. Announcement • May 14
Ventas, Inc. Declares Quarterly Dividend, Payable on July 16, 2026 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.52 per common share. The dividend will be payable in cash on July 16, 2026, to stockholders of record as of the close of business on June 30, 2026. Announcement • Apr 29
Ventas, Inc. Increases Earnings Guidance for the Full Year 2026 Ventas, Inc. increased earnings guidance for the full year 2026. For the year, the company now expects Attributable Net Income Per Share Range of $0.56 to $0.63 against previous range of $0.52 to $0.62 and Attributable Net Income Per Share Midpoint of $0.60 against previous guidance of $0.57. The increase in the Company’s guidance is primarily the result of higher property performance led by SHOP and accretion from investment activity, partially offset by the market expectation of higher interest rates. Net income attributable to common stockholders to be in the range of $282 million to $317 million against previous range of $260 million to $310 million. Reported Earnings • Apr 28
First quarter 2026 earnings released: EPS: US$0.12 (vs US$0.11 in 1Q 2025) First quarter 2026 results: EPS: US$0.12 (up from US$0.11 in 1Q 2025). Revenue: US$1.66b (up 23% from 1Q 2025). Net income: US$55.9m (up 19% from 1Q 2025). Profit margin: 3.4% (down from 3.5% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 2.6% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 86% per year but the company’s share price has only increased by 23% per year, which means it is significantly lagging earnings growth. Announcement • Apr 03
Ventas, Inc. to Report Q1, 2026 Results on Apr 27, 2026 Ventas, Inc. announced that they will report Q1, 2026 results After-Market on Apr 27, 2026 Announcement • Apr 02
Ventas, Inc., Annual General Meeting, May 13, 2026 Ventas, Inc., Annual General Meeting, May 13, 2026. Upcoming Dividend • Mar 24
Upcoming dividend of US$0.52 per share Eligible shareholders must have bought the stock before 31 March 2026. Payment date: 16 April 2026. Trailing yield: 2.5%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (7.1%). Buy Or Sell Opportunity • Mar 05
Now 22% undervalued Over the last 90 days, the stock has risen 5.2% to US$84.23. The fair value is estimated to be US$108, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings are also forecast to grow by 26% per annum over the same time period. Announcement • Feb 21
Ventas, Inc. Announces Resignation of Gregory R. Liebbe as Senior Vice President, Chief Accounting Officer and Controller, Effective February 27, 2026 On February 16, 2026, announced that Gregory R. Liebbe, Senior Vice President, Chief Accounting Officer and Controller, informed Ventas, Inc. (company) that he is resigning to pursue other opportunities. Mr. Liebbe's last day of employment with the company will be February 27, 2026. Mr. Liebbe's decision to resign is not the result of any disagreement with the company, including with respect to any matter relating to the company's accounting practices or financial reporting. Concurrent with Mr. Liebbe’s departure, Mr. Probst will assume the responsibilities of Chief Accounting Officer on an interim basis while the Company conducts a comprehensive search for a permanent successor. Recent Insider Transactions • Feb 16
Executive VP recently sold US$3.0m worth of stock On the 11th of February, Carey Roberts sold around 36k shares on-market at roughly US$85.00 per share. This transaction amounted to 32% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$4.5m more than they bought in the last 12 months. Declared Dividend • Feb 08
Fourth quarter dividend increased to US$0.52 Dividend of US$0.52 is 8.3% higher than last year. Ex-date: 31st March 2026 Payment date: 16th April 2026 Dividend yield will be 2.4%, which is lower than the industry average of 7.4%. Reported Earnings • Feb 07
Full year 2025 earnings released: FFO per share: US$3.6 (vs US$3.17 in FY 2024) Full year 2025 results: FFO per share: US$3.6 (up from US$3.17 in FY 2024). Revenue: US$5.82b (up 19% from FY 2024). Funds from operations (FFO): US$1.62b (up 24% from FY 2024). FFO margin: 28% (up from 27% in FY 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in Europe. Over the last 3 years on average, earnings per share has increased by 85% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Announcement • Jan 15
Ventas, Inc. to Report Q4, 2025 Results on Feb 05, 2026 Ventas, Inc. announced that they will report Q4, 2025 results After-Market on Feb 05, 2026 Declared Dividend • Dec 14
Third quarter dividend of US$0.48 announced Shareholders will receive a dividend of US$0.48. Ex-date: 31st December 2025 Payment date: 15th January 2026 Dividend yield will be 2.5%, which is lower than the industry average of 7.4%. Announcement • Dec 11
Ventas, Inc. Declares Quarterly Dividend, Payable on January 15, 2026 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.48 per common share. The dividend will be payable in cash on January 15, 2026, to stockholders of record as of the close of business on December 31, 2025. Announcement • Nov 18
Ventas, Inc. Announces Retirement of Peter J. Bulgarelli, Evp, Outpatient Medical & Research, Effective May 1, 2026 Ventas, Inc. announced that Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research has informed the Company of his intention to retire on May 1, 2026. Ventas will commence a search process to identify a successor. Bulgarelli oversees Ventas’s Outpatient Medical & Research and Triple-Net Leased Healthcare businesses and its wholly-owned property management and leasing subsidiary, Lillibridge Healthcare Services. He joined Ventas in 2018 following a twenty-eight-year career at Jones Lang LaSalle, where he led the real estate firm’s healthcare, life sciences, higher education and public sector businesses. Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: US$0.14 (vs US$0.046 in 3Q 2024) Third quarter 2025 results: EPS: US$0.14 (up from US$0.046 in 3Q 2024). Revenue: US$1.49b (up 21% from 3Q 2024). Net income: US$66.0m (up 243% from 3Q 2024). Profit margin: 4.4% (up from 1.6% in 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Global Health Care REITs industry. Over the last 3 years on average, earnings per share has increased by 78% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Announcement • Oct 30
Ventas, Inc. Increases Earnings Guidance for the Full Year 2025 Ventas, Inc. increased earnings guidance for the full year 2025. For the year, the company now expects attributable Net Income Per Share in the range of $0.49 - $0.52 compared to previous guidance range of $0.47 - $0.52. Announcement • Oct 07
Ventas, Inc. to Report Q3, 2025 Results on Oct 29, 2025 Ventas, Inc. announced that they will report Q3, 2025 results After-Market on Oct 29, 2025 Declared Dividend • Sep 22
Second quarter dividend of US$0.48 announced Shareholders will receive a dividend of US$0.48. Ex-date: 30th September 2025 Payment date: 16th October 2025 Dividend yield will be 2.8%, which is lower than the industry average of 7.4%. Announcement • Sep 19
Ventas Declares Quarterly Dividend, Payable on October 16, 2025 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.48 per common share. The dividend will be payable in cash on October 16, 2025, to stockholders of record as of the close of business on September 30, 2025. Reported Earnings • Jul 31
Second quarter 2025 earnings released: EPS: US$0.15 (vs US$0.048 in 2Q 2024) Second quarter 2025 results: EPS: US$0.15 (up from US$0.048 in 2Q 2024). Revenue: US$1.42b (up 19% from 2Q 2024). Net income: US$68.3m (up 252% from 2Q 2024). Profit margin: 4.8% (up from 1.6% in 2Q 2024). Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Announcement • Jul 31
Ventas, Inc. Revises Earnings Guidance for the Year 2025 Ventas, Inc. revised earnings guidance for the year 2025. For the year, the company revised the Attributable Net Income Per Share Range of $0.47 - $0.52 per share compared to previous guidance of $0.43 - $0.53 per share a year ago. Announcement • Jul 08
Ventas, Inc. to Report Q2, 2025 Results on Jul 30, 2025 Ventas, Inc. announced that they will report Q2, 2025 results After-Market on Jul 30, 2025 Upcoming Dividend • Jun 23
Upcoming dividend of US$0.48 per share Eligible shareholders must have bought the stock before 30 June 2025. Payment date: 17 July 2025. Trailing yield: 3.1%. Lower than top quartile of British dividend payers (5.6%). Lower than average of industry peers (6.4%). Recent Insider Transactions • Jun 01
Executive VP recently sold US$1.5m worth of stock On the 30th of May, Carey Roberts sold around 24k shares on-market at roughly US$64.23 per share. This transaction amounted to 21% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$2.7m more than they bought in the last 12 months. Declared Dividend • May 19
First quarter dividend of US$0.48 announced Shareholders will receive a dividend of US$0.48. Ex-date: 30th June 2025 Payment date: 17th July 2025 Dividend yield will be 2.9%, which is lower than the industry average of 7.4%. Announcement • May 14
Ventas, Inc. Declares Quarterly Cash Dividend, Payable on July 17, 2025 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.48 per common share. The dividend will be payable in cash on July 17, 2025 to stockholders of record as of the close of business on June 30, 2025. Reported Earnings • May 01
First quarter 2025 earnings released: EPS: US$0.11 (vs US$0.035 loss in 1Q 2024) First quarter 2025 results: EPS: US$0.11 (up from US$0.035 loss in 1Q 2024). Revenue: US$1.36b (up 15% from 1Q 2024). Net income: US$46.9m (up US$61.2m from 1Q 2024). Profit margin: 3.5% (up from net loss in 1Q 2024). Revenue is forecast to grow 8.0% p.a. on average during the next 3 years, while revenues in the Health Care REITs industry in Europe are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • May 01
Ventas, Inc. Reaffirms Earnings Guidance for the Full Year 2025 Ventas, Inc. reaffirmed earnings guidance for the full year 2025. For the year, the company expects Attributable Net Income Per Share Range in the range of $0.42 - $0.53. Announcement • Apr 05
Ventas, Inc. to Report Q1, 2025 Results on Apr 30, 2025 Ventas, Inc. announced that they will report Q1, 2025 results After-Market on Apr 30, 2025 Upcoming Dividend • Mar 24
Upcoming dividend of US$0.48 per share Eligible shareholders must have bought the stock before 31 March 2025. Payment date: 17 April 2025. Trailing yield: 2.9%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (6.9%). Announcement • Mar 20
Ventas, Inc., Annual General Meeting, May 13, 2025 Ventas, Inc., Annual General Meeting, May 13, 2025. Buy Or Sell Opportunity • Mar 06
Now 22% undervalued Over the last 90 days, the stock has risen 11% to US$68.07. The fair value is estimated to be US$87.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.1% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 7.2% per annum. Earnings are also forecast to grow by 31% per annum over the same time period. Declared Dividend • Feb 16
Fourth quarter dividend increased to US$0.48 Dividend of US$0.48 is 6.7% higher than last year. Ex-date: 31st March 2025 Payment date: 17th April 2025 Dividend yield will be 2.8%, which is lower than the industry average of 7.4%. Announcement • Feb 13
Ventas, Inc. Declares Quarterly Dividend, Payable on April 17, 2025 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.48 per share, representing a 7% increase, on the strength of the Company’s results and its positive outlook. The dividend will be payable in cash on April 17, 2025 to stockholders of record on March 31, 2025. Reported Earnings • Feb 13
Full year 2024 earnings released: EPS: US$0.20 (vs US$0.10 loss in FY 2023) Full year 2024 results: EPS: US$0.20 (up from US$0.10 loss in FY 2023). Revenue: US$4.92b (up 9.4% from FY 2023). Net income: US$81.2m (up US$122.1m from FY 2023). Profit margin: 1.6% (up from net loss in FY 2023). Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 2.9% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Announcement • Feb 13
Ventas, Inc. Provides Earnings Guidance for the Year 2025 Ventas, Inc. provided earnings guidance for the year 2025. For the year, the company expects attributable net income per share to be in the range of USD 0.42 to USD 0.53. The Company’s full year guidance for 2025 Attributable Net Income per share of USD 0.48 at the midpoint of the range compares to 2024 Attributable Net Income of USD 0.19. Announcement • Jan 17
Ventas, Inc. to Report Q4, 2024 Results on Feb 12, 2025 Ventas, Inc. announced that they will report Q4, 2024 results After-Market on Feb 12, 2025 Declared Dividend • Dec 16
Third quarter dividend of US$0.45 announced Dividend of US$0.45 is the same as last year. Ex-date: 31st December 2024 Payment date: 16th January 2025 Dividend yield will be 3.0%, which is lower than the industry average of 7.4%. Announcement • Dec 11
Ventas Declares Fourth Quarter 2024 Dividend, Payable in Cash on January 16, 2025 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on January 16, 2025 to stockholders of record as of the close of business on December 31, 2024. Announcement • Nov 02
Ventas, Inc. Revises Earnings Guidance for the Year 2024 Ventas, Inc. revised earnings guidance for the year 2024. For the year, the company expects net income attributable to common stockholders to be in the range of $0.09 to $0.13 compared to previous guidance of $0.07 to $0.13. Reported Earnings • Nov 01
Third quarter 2024 earnings released: FFO per share: US$0.8 (vs US$0.74 in 3Q 2023) Third quarter 2024 results: FFO per share: US$0.8 (up from US$0.74 in 3Q 2023). Revenue: US$1.23b (up 7.9% from 3Q 2023). Funds from operations (FFO): US$331.5m (up 12% from 3Q 2023). FFO margin: 27% (up from 26% in 3Q 2023). Revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 108 percentage points per year, which is a significant difference in performance. Announcement • Oct 05
Ventas, Inc. to Report Q3, 2024 Results on Oct 30, 2024 Ventas, Inc. announced that they will report Q3, 2024 results After-Market on Oct 30, 2024 Declared Dividend • Sep 20
Second quarter dividend of US$0.45 announced Dividend of US$0.45 is the same as last year. Ex-date: 1st October 2024 Payment date: 17th October 2024 Dividend yield will be 2.9%, which is lower than the industry average of 7.4%. Announcement • Sep 19
Ventas, Inc. has filed a Follow-on Equity Offering in the amount of $2 billion. Ventas, Inc. has filed a Follow-on Equity Offering in the amount of $2 billion.
Security Name: Common Stock
Security Type: Common Stock
Security Features: Income Trust
Transaction Features: At the Market Offering Announcement • Sep 18
Ventas, Inc. Declares Third Quarter 2024 Dividend, Payable on October 17, 2024 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on October 17, 2024 to stockholders of record as of the close of business on October 1, 2024. Announcement • Sep 17
Ventas, Inc. (NYSE:VTR) acquired Five performing LTAC assets for approximately $190 million. Ventas, Inc. (NYSE:VTR) acquired Five performing LTAC assets for approximately $190 million on September 16, 2024.
Ventas, Inc. (NYSE:VTR) completed the acquisition of Five performing LTAC assets on September 16, 2024. New Risk • Sep 10
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.2m sold). New Risk • Sep 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.2m sold). New Risk • Sep 06
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.2m sold). New Risk • Aug 18
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.2m sold). New Risk • Aug 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (2.6% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.2m sold). New Risk • Aug 02
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 1.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.1x net interest cover). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (1.0% increase in shares outstanding). Significant insider selling over the past 3 months (US$1.6m sold). Reported Earnings • Aug 02
Second quarter 2024 earnings released: EPS: US$0.048 (vs US$0.26 in 2Q 2023) Second quarter 2024 results: EPS: US$0.048 (down from US$0.26 in 2Q 2023). Revenue: US$1.20b (up 8.9% from 2Q 2023). Net income: US$19.4m (down 81% from 2Q 2023). Profit margin: 1.6% (down from 9.4% in 2Q 2023). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 103 percentage points per year, which is a significant difference in performance. Announcement • Aug 02
Ventas, Inc. Updates Earnings Guidance for the Full Year 2024 Ventas, Inc. updated earnings guidance for the full year 2024. For the year, the company expected attributable net income per share in the range of $0.07 to $0.13 as compared to previous range guidance range of $0.03 to $0.11 and attributable net income per share midpoint of $0.10 as compared to previous range guidance range of $0.07. Declared Dividend • May 17
First quarter dividend of US$0.45 announced Dividend of US$0.45 is the same as last year. Ex-date: 1st July 2024 Payment date: 18th July 2024 Dividend yield will be 3.7%, which is lower than the industry average of 7.4%. Announcement • May 16
Ventas, Inc. Declares Second Quarter 2024 Dividend, Payable on July 18, 2024 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on July 18, 2024 to stockholders of record as of the close of business on July 1, 2024. Recent Insider Transactions • May 09
Executive VP & CFO recently sold US$872k worth of stock On the 7th of May, Robert Probst sold around 19k shares on-market at roughly US$47.11 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months. Announcement • May 03
Ventas, Inc. Updates Earnings Guidance for the Full Year 2024 Ventas, Inc. updated earnings guidance for the full year 2024. For the year, the company expected attributable net income per share in the range of $0.03 to $0.11 as compared to previous range guidance range of $0.00 to $0.11 and attributable net income per share midpoint of $0.07 as compared to previous range guidance range of $0.06. Reported Earnings • May 02
First quarter 2024 earnings released: US$0.035 loss per share (vs US$0.044 profit in 1Q 2023) First quarter 2024 results: US$0.035 loss per share (down from US$0.044 profit in 1Q 2023). Revenue: US$1.20b (up 12% from 1Q 2023). Net loss: US$14.3m (down 182% from profit in 1Q 2023). Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 2.0% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 58% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Apr 04
Ventas, Inc. to Report Q1, 2024 Results on May 01, 2024 Ventas, Inc. announced that they will report Q1, 2024 results After-Market on May 01, 2024 Upcoming Dividend • Mar 21
Upcoming dividend of US$0.45 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 18 April 2024. Trailing yield: 4.1%. Lower than top quartile of British dividend payers (6.3%). Lower than average of industry peers (7.7%). Declared Dividend • Mar 15
Fourth quarter dividend of US$0.45 announced Dividend of US$0.45 is the same as last year. Ex-date: 28th March 2024 Payment date: 18th April 2024 Dividend yield will be 4.2%, which is lower than the industry average of 7.4%. Announcement • Mar 13
Ventas, Inc. Declares First Quarter 2024 Dividend, Payable on April 18, 2024 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on April 18, 2024 to stockholders of record as of the close of business on April 1, 2024. New Risk • Feb 26
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Earnings are forecast to decline by an average of 0.4% per year for the foreseeable future. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Reported Earnings • Feb 15
Full year 2023 earnings released: US$0.10 loss per share (vs US$0.12 loss in FY 2022) Full year 2023 results: US$0.10 loss per share (improved from US$0.12 loss in FY 2022). Revenue: US$4.50b (up 9.3% from FY 2022). Net loss: US$41.0m (loss narrowed 14% from FY 2022). Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 2.8% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 79 percentage points per year, which is a significant difference in performance. Announcement • Feb 15
Ventas, Inc. Provides Earnings Guidance for the Year 2024 Ventas, Inc. provided earnings guidance for the year 2024. For the year, the company expects net income attributable to common stockholders to be in the range of USD 0 to USD 47 million or USD 0.11 per share. Announcement • Jan 24
Ventas, Inc. to Report Q4, 2023 Results on Feb 14, 2024 Ventas, Inc. announced that they will report Q4, 2023 results After-Market on Feb 14, 2024 Upcoming Dividend • Dec 22
Upcoming dividend of US$0.45 per share at 3.6% yield Eligible shareholders must have bought the stock before 29 December 2023. Payment date: 18 January 2024. Trailing yield: 3.6%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (6.6%). Announcement • Dec 06
Ventas Declares Dividend for the Fourth Quarter 2023, Payable on January 18, 2024 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on January 18, 2024 to stockholders of record as of the close of business on January 2, 2024. Announcement • Nov 04
Ventas, Inc. Revises Earnings Guidance for the Year 2023 Ventas, Inc. revised earnings guidance for the year 2023. The company now expects attributable Net Income Per Share Range to be $0.14 - $0.17 against previous guidance of $0.22 - $0.32. Reported Earnings • Nov 03
Third quarter 2023 earnings released: US$0.18 loss per share (vs US$0.003 profit in 3Q 2022) Third quarter 2023 results: US$0.18 loss per share (down from US$0.003 profit in 3Q 2022). Revenue: US$1.15b (up 11% from 3Q 2022). Net loss: US$71.1m (down US$72.4m from profit in 3Q 2022). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.1% growth forecast for the Health Care REITs industry in the United Kingdom. Announcement • Oct 19
Ventas, Inc. to Report Q3, 2023 Results on Nov 02, 2023 Ventas, Inc. announced that they will report Q3, 2023 results After-Market on Nov 02, 2023 Upcoming Dividend • Sep 22
Upcoming dividend of US$0.45 per share at 4.2% yield Eligible shareholders must have bought the stock before 29 September 2023. Payment date: 12 October 2023. Trailing yield: 4.2%. Lower than top quartile of British dividend payers (6.2%). Lower than average of industry peers (7.0%). Announcement • Sep 14
Ventas, Inc. Declares Third Quarter 2023 Dividend, Payable in Cash on October 12, 2023 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on October 12, 2023 to stockholders of record as of the close of business on October 2, 2023. Announcement • Sep 12
Land & Buildings Investment Management Sends Letter to Shareholders of Ventas On September 11, 2023, Land & Buildings Investment Management LLC announced that it has sent a letter to shareholders of Ventas Inc, stating that the fundamentals of senior housing are strengthening across multiple key pillars with accelerating demographic-driven needs-based demand, declining new competitive supply growth and waning expense headwinds, yet the Company has generated a negative total return year-to-date, underperforming Welltower by 33%, and despite the continued senior housing strength and recovery, Company has failed to outperform the Healthcare REIT Index. In addition, Land & Buildings Investment Management stated that it believes meaningful board change is necessary to restore accountability and maximize value for all stakeholders, despite its continued disappointment with management and the board, it remains open to continuing dialogue with the Company regarding opportunities to restore accountability and proper governance, improve performance and drive shareholder value for the benefit of all the Company stakeholders. Buying Opportunity • Aug 11
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.1%. The fair value is estimated to be US$54.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 3.9% over the last 3 years. Earnings per share has declined by 86%. Revenue is forecast to grow by 13% in 2 years. Earnings is forecast to grow by 84% in the next 2 years. Reported Earnings • Aug 04
Second quarter 2023 earnings released: EPS: US$0.26 (vs US$0.11 loss in 2Q 2022) Second quarter 2023 results: EPS: US$0.26 (up from US$0.11 loss in 2Q 2022). Revenue: US$1.11b (up 8.4% from 2Q 2022). Net income: US$103.5m (up US$145.9m from 2Q 2022). Profit margin: 9.4% (up from net loss in 2Q 2022). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.2% growth forecast for the Health Care REITs industry in Europe. Announcement • Jul 22
Ventas, Inc. to Report Q2, 2023 Results on Aug 03, 2023 Ventas, Inc. announced that they will report Q2, 2023 results After-Market on Aug 03, 2023 Upcoming Dividend • Jun 23
Upcoming dividend of US$0.45 per share at 4.0% yield Eligible shareholders must have bought the stock before 30 June 2023. Payment date: 13 July 2023. Trailing yield: 4.0%. Lower than top quartile of British dividend payers (5.9%). Lower than average of industry peers (7.3%). Announcement • May 17
Ventas, Inc. Declares Second Quarter 2023 Dividend, Payable on July 13, 2023 Ventas, Inc. announced that its Board of Directors has declared a quarterly dividend of $0.45 per common share. The dividend will be payable in cash on July 13, 2023 to stockholders of record as of the close of business on July 3, 2023. Reported Earnings • May 09
First quarter 2023 earnings released: EPS: US$0.044 (vs US$0.097 in 1Q 2022) First quarter 2023 results: EPS: US$0.044 (down from US$0.097 in 1Q 2022). Revenue: US$1.08b (up 6.4% from 1Q 2022). Net income: US$17.5m (down 55% from 1Q 2022). Profit margin: 1.6% (down from 3.8% in 1Q 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 5.2% growth forecast for the Health Care REITs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 118 percentage points per year, which is a significant difference in performance. Announcement • May 09
Ventas, Inc. Provides Earnings Guidance for the Full Year 2023 Ventas, Inc. provided earnings guidance for the full year 2023. For the year, the company expects attributable net income per share to be between $0.20 to $0.34 and attributable Net Income Per Share Midpoint of $0.27. Reported Earnings • Feb 10
Full year 2022 earnings released: US$0.12 loss per share (vs US$0.13 profit in FY 2021) Full year 2022 results: US$0.12 loss per share (down from US$0.13 profit in FY 2021). Revenue: US$4.13b (up 8.1% from FY 2021). Net loss: US$47.4m (down 197% from profit in FY 2021). Revenue is forecast to grow 5.7% p.a. on average during the next 2 years, compared to a 5.2% growth forecast for the REITs industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 83 percentage points per year, which is a significant difference in performance. Announcement • Feb 10
Ventas, Inc. Provides Earnings Guidance for the Year 2023 Ventas, Inc. provided earnings guidance for the year 2023. For the year, the company expects attributable net income per share to be between $0.20 to $0.34. Buying Opportunity • Feb 05
Now 22% undervalued Over the last 90 days, the stock is up 28%. The fair value is estimated to be US$66.20, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making. Announcement • Jan 24
Ventas, Inc. Appoints J. Justin Hutchens, Executive Vice President, Senior Housing, to Additional Role of Chief Investment Officer Ventas, Inc. announced that J. Justin Hutchens, Executive Vice President, Senior Housing, has been appointed to the additional role of Chief Investment Officer, effective immediately. In his expanded role, Hutchens will be responsible for Ventas’s capital allocation strategy and execution across the enterprise in addition to his current responsibility for the Company’s Senior Housing portfolio. He will oversee both the Senior Housing and Investments teams and continue to report directly to Ventas Chairman and CEO Debra A. Cafaro. With more than 25 years of experience in both REITs and senior housing, Hutchens has significant investment and capital allocation expertise and a record of proven success. He has led Ventas’s Senior Housing business since joining the Company in early 2020, with responsibility for more than 800 communities representing nearly half of the Company’s portfolio. Hutchens previously served as President and Chief Investment Officer of HCP and Chief Executive Officer and President of National Health Investors. Hutchens joined Ventas from HC-One, the UK’s care homes operator with over 325 locations and over 22,000 employees, where he served as Chief Executive Officer from 2017 to 2020. Hutchens will assume the responsibilities of John D. Cobb, who will be leaving the Company. Cobb has agreed to remain at the Company as a strategic advisor through mid-February. 
